VALNEVA to Present on Lyme, Chikungunya Vax Candidates

Valneva SE (“Valneva” or “the Company”), a biotech company developing and commercializing vaccines for infectious diseases with major unmet needs, announced today it will present on its Lyme disease and chikungunya vaccine candidates on April 16th, 2019 at the 19th World Vaccine Congress in Washington, D.C.

Valneva’s Chief Executive Officer, Thomas Lingelbach, will provide an update and discuss next steps for VLA15, the Company’s vaccine candidate against Lyme disease. Lyme is the most commonly occurring vector borne illness in the Northern Hemisphere with an estimated 300,000 Americans contracting the disease each year[1]. VLA15 has been shortlisted in the “Best Prophylactic Vaccine” category of the 2019 Vaccine Industry Excellence (ViE) Awards, held in conjunction with the World Vaccine Congresseach year.

Valneva’s Chief Medical Officer, Dr. Wolfgang Bender, will also present on the Phase 1 development of the Company’s chikungunya vaccine candidate, VLA1553. He will also discuss next steps for the potential single-shot vaccine.

https://www.marketscreener.com/VALNEVA-54466/news/VALNEVA-to-Present-on-Lyme-and-Chikungunya-Vaccine-Candidates-at-the-19th-World-Vaccine-Congress-28378154/